An observational study in Solid Cancers, sponsored by University Hospital, Angers. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by University Hospital, Angers · Observational
The thoraco-abdomino-pelvic (TAP) scanner is crucial for assessing and monitoring solid cancers. However, advancements in scanner technology have led to a significant increase in data volume, from 100 images per exam 20 years ago to 2,000 today. The rising number of cancer cases and treatments requiring closer monitoring further strain the workload, prolonging interpretation time and causing delays in therapeutic management and adjustments. The limited number of radiologists contributes to this saturation, increasing the risk of missing metastatic lesions, especially in the lungs, liver, bones, peritoneum, and lymph nodes. The RECIST 1.1 criteria, introduced 15 years ago for standardized follow-up, are useful but time-consuming to implement, resulting in only a small fraction of oncology CT reports using them.
The LiFE study consists in retrospectively interpreting the TAP scans of patients who have agreed to take part in the study at two separate times, once without the LiFlow tool and once with it, at least 8 weeks after the scan date. To avoid any memory effect, a washout period of 8 weeks will be observed between these two interpretations. The study will involve 10 radiologists and 400 patients. Each scan will be interpreted twice by the same doctor (with and without the LF tool). During the second retrospective interpretation, the radiologist will assess the impact of of the additional lesions discovered by LiFlow on the patient's therapeutic management. The notion of change in management is defined by a change in treatment, such as a change in surgical technique, a change in chemotherapy or an indication for a treatment not initially planned. In addition, for these lesions, a gold standard will be obtained (an opinion from one or two other radiologists and/or other characterization imaging and/or biopsy/histology and/or follow-up of the lesion).
The aim of the study is to validate the time saved on interpretations and reports, and to improve the accuracy of TAP scan interpretation.
University Hospital, Angers is the lead sponsor of 477 studies on the registry; 119 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients treated for solid cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
two interpretations (with and without Liflow, oncology imaging tool).
Time elapsed between opening and closing, oncology interpretation completed, of the same file interpreted
Time frame: 1 day
Number of additional relevant lesions discovered
Time frame: Day 1
Duration recorded for examinations with no relevant lesions and pathological examinations
Time frame: Day 1
Recorded times for initial and follow-up examinations
Time frame: Day 1
Location and size of lesion(s) on report and nature of primary tumor in patient file
Time frame: Day 1
Number of lesions detected
relevant or doubtful lesions by reading with or without Liflow
Time frame: Day 1
Number of lesions whose discovery would have led to a change in treatment
change in surgical technique, change in chemotherapy, indication of a treatment not initially planned
Time frame: day 1
Number of lesions not retained
Time frame: day 1
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.